Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. GNK
2. INTC
3. DSX
4. III
5. TTEC
6. DAL
7. AWK
8. SPCX
9. HAWK
10. RPAY

Go back to Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements
(NYSE: ANRO) Delayed: 22.74 +0.95 (4.36%)
Previous Close $21.79    52 Week High $ 
Open $22.50    52 Week Low $ 
Day High $23.51    P/E N/A 
Day Low $21.76    EPS $ 
Volume 558,218